A high throughput protein microarray approach to classify HIV monoclonal antibodies and variant antigens

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Dotsey, Emmanuel Y ^a   Gorlani, Andrea ^a,d   Ingale, Sampat ^b   Achenbach, Chad J ^c   Forthal, Donald N ^a   Felgner, Philip L ^a   Gach, Johannes S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d ModiQuest Research   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GLYCAN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 41; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 240 D; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 447 52D; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY 5F3; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY DEN3; MONOCLONAL ANTIBODY F105; MONOCLONAL ANTIBODY F425 B4E8; MONOCLONAL ANTIBODY VRC01; MONOCLONAL ANTIBODY VRC03; MONOCLONAL ANTIBODY Z13E1; REV PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; PEPTIDE; POLYSACCHARIDE;

ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIVIRAL THERAPY; ARTICLE; BINDING AFFINITY; CLADISTICS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; EC50; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; NONHUMAN; PROTEIN MICROARRAY; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; AMINO ACID SEQUENCE; BLOOD; CHEMISTRY; CLUSTER ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; IMMUNOLOGY; KINETICS; MOLECULAR GENETICS; PROCEDURES; SEQUENCE ALIGNMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1; PRIMATES;

AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CLUSTER ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIGH-THROUGHPUT SCREENING ASSAYS; HIV ANTIBODIES; HIV ANTIGENS; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; PEPTIDES; POLYSACCHARIDES; PROTEIN ARRAY ANALYSIS; SEQUENCE ALIGNMENT;

EID: 84929224718     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125581     Document Type: Article

References (52)

1. West AP Jr., Scharf L, Scheid JF, Klein F, Bjorkman PJ, Nussenzweig MC. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell. 2014; 156(4):633-48. doi: 10.1016/j.cell.2014.01.052 PMID: 24529371; PubMed Central PMCID: PMC4041625.
2. Overbaugh J, Morris L. The Antibody Response against HIV-1. Cold Spring Harbor perspectives in medicine. 2012; 2(1):a007039. doi: 10.1101/cshperspect.a007039 PMID: 22315717; PubMed Central PMCID: PMC3253031.
3. McCoy LE, Weiss RA. Neutralizing antibodies to HIV-1 induced by immunization. The Journal of experimental medicine. 2013; 210(2):209-23. doi: 10.1084/jem.20121827 PMID: 23401570; PubMed Central PMCID: PMC3570100.
4. Falkowska E, Le KM, Ramos A, Doores KJ, Lee JH, Blattner C, et al. Broadly Neutralizing HIV Antibodies Define a Glycan-Dependent Epitope on the Prefusion Conformation of gp41 on Cleaved Envelope Trimers. Immunity. 2014; 40(5):657-68. doi: 10.1016/j.immuni.2014.04.009 PMID: 24768347.
5. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity. 2012; 37(3):412-25. doi: 10.1016/j.immuni.2012.08.012 PMID: 22999947.
6. Kwong PD, Mascola JR, Nabel GJ. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nature reviews Immunology. 2013; 13(9):693-701. doi: 10.1038/nri3516 PMID: 23969737.
7. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, Grise H, et al. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol. 2006; 80(5):2515-28. PMID: 16474158.
8. Alter G, Moody MA. The humoral response to HIV-1: new insights, renewed focus. The Journal of infectious diseases. 2010; 202 Suppl 2:S315-22. doi: 10.1086/655654 PMID: 20846039; PubMed Central PMCID: PMC2945610.
9. Forthal DN, Moog C. Fc receptor-mediated antiviral antibodies. Current opinion in HIV and AIDS. 2009; 4(5):388-93. doi: 10.1097/COH.0b013e32832f0a89 PMID: 20048702; PubMed Central PMCID: PMC2882066.
10. Hope TJ. Moving ahead an HIV vaccine: to neutralize or not, a key HIV vaccine question. Nature medicine. 2011; 17(10):1195-7. doi: 10.1038/nm.2528 PMID: 21988997.
11. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol. 2012; 86(21):11521-32. doi: 10.1128/JVI.01023-12 PMID: 22896626; PubMed Central PMCID: PMC3486290.
12. Veillette M, Desormeaux A, Medjahed H, Gharsallah NE, Coutu M, Baalwa J, et al. Interaction with cellular CD4 exposes HIV-1 envelope epitopes targeted by antibody-dependent cell-mediated cytotoxicity. J Virol. 2014; 88(5):2633-44. doi: 10.1128/JVI.03230-13 PMID: 24352444; PubMed Central PMCID: PMC3958102.
13. Smalls-Mantey A, Doria-Rose N, Klein R, Patamawenu A, Migueles SA, Ko SY, et al. Antibody-dependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol. 2012; 86(16):8672-80. doi: 10.1128/JVI.00287-12 PMID: 22674985; PubMed Central PMCID: PMC3421757.
14. Wren LH, Chung AW, Isitman G, Kelleher AD, Parsons MS, Amin J, et al. Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology. 2013; 138(2):116-23. doi: 10.1111/imm.12016 PMID: 23173935; PubMed Central PMCID: PMC3575764.
15. Tudor D, Bomsel M. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcgammaRI-dependent manner. Aids. 2011; 25(6):751-9. doi: 10.1097/QAD.0b013e32834507bd PMID: 21330910.
16. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. Aids. 2009; 23 (8):897-906. doi: 10.1097/QAD.0b013e328329f97d PMID: 19414990; PubMed Central PMCID: PMC3652655.
17. Baum E, Badu K, Molina DM, Liang X, Felgner PL, Yan G. Protein microarray analysis of antibody responses to Plasmodium falciparum in western Kenyan highland sites with differing transmission levels. PLOS one. 2013; 8(12):e82246. doi: 10.1371/journal.pone.0082246 PMID: 24312649; PubMed Central PMCID: PMC3846730.
18. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, Weiss GE, et al. A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107 (15):6958-63. doi: 10.1073/pnas.1001323107 PMID: 20351286; PubMed Central PMCID: PMC2872454.
19. Davies DH, McCausland MM, Valdez C, Huynh D, Hernandez JE, Mu Y, et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol. 2005; 79(18):11724-33. doi: 10.1128/JVI.79.18.11724-11733.2005 PMID: 16140750; PubMed Central PMCID: PMC1212608.
20. Davies DH, Molina DM, Wrammert J, Miller J, Hirst S, Mu Y, et al. Proteome-wide analysis of the serological response to vaccinia and smallpox. Proteomics. 2007; 7(10):1678-86. doi: 10.1002/pmic.200600926 PMID: 17443847.
21. Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, et al. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J Virol. 2007; 81(8):4033-43. Epub 2007/02/09. doi: JVI.02588-06 [pii] doi: 10.1128/JVI.02588-06 PMID: 17287272.
22. Nakamura KJ, Gach JS, Jones L, Semrau K, Walter J, Bibollet-Ruche F, et al. 4E10-resistant HIV-1 isolated from four subjects with rare membrane-proximal external region polymorphisms. PLOS one. 2010; 5(3):e9786. doi: 10.1371/journal.pone.0009786 PMID: 20352106; PubMed Central PMCID: PMC2843716.
23. Brunel FM, Zwick MB, Cardoso RM, Nelson JD, Wilson IA, Burton DR, et al. Structure-function analysis of the epitope for 4E10, a broadly neutralizing human immunodeficiency virus type 1 antibody. J Virol. 2006; 80(4):1680-7. doi: 10.1128/JVI.80.4.1680-1687.2006 PMID: 16439525; PubMed Central PMCID: PMC1367132.
24. Ingale S, Gach JS, Zwick MB, Dawson PE. Synthesis and analysis of the membrane proximal external region epitopes of HIV-1. Journal of peptide science: an official publication of the European Peptide Society. 2010; 16(12):716-22. doi: 10.1002/psc.1325 PMID: 21104968.
25. Liu J, Deng Y, Dey AK, Moore JP, Lu M. Structure of the HIV-1 gp41 membrane-proximal ectodomain region in a putative prefusion conformation. Biochemistry. 2009; 48(13):2915-23. doi: 10.1021/bi802303b PMID: 19226163; PubMed Central PMCID: PMC2765501.
26. Morikawa Y, Overton HA, Moore JP, Wilkinson AJ, Brady RL, Lewis SJ, et al. Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro. AIDS research and human retroviruses. 1990; 6(6):765-73. PMID: 2364018.
27. Wang YH, Davies AH, Jones IM. Expression and purification of glutathione S-transferase-tagged HIV-1 gp120: no evidence of an interaction with CD26. Virology. 1995; 208(1):142-6. doi: 10.1006/viro.1995.1137 PMID: 11831694.
28. Cheng-Mayer C, Weiss C, Seto D, Levy JA. Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. Proceedings of the National Academy of Sciences of the United States of America. 1989; 86(21):8575-9. PMID: 2813413; PubMed Central PMCID: PMC298325.
29. Sellhorn G, Caldwell Z, Mineart C, Stamatatos L. Improving the expression of recombinant soluble HIV Envelope glycoproteins using pseudo-stable transient transfection. Vaccine. 2009; 28(2):430-6. doi: 10.1016/j.vaccine.2009.10.028 PMID: 19857451.
30. Stanfield RL, Julien JP, Pejchal R, Gach JS, Zwick MB, Wilson IA. Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope. Journal of molecular biology. 2011; 414 (3):460-76. doi: 10.1016/j.jmb.2011.10.014 PMID: 22033480; PubMed Central PMCID: PMC3245871.
31. Gupta S, Gach JS, Becerra JC, Phan TB, Pudney J, Moldoveanu Z, et al. The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLOS pathogens. 2013; 9(11):e1003776. doi: 10.1371/journal.ppat.1003776 PMID: 24278022; PubMed Central PMCID: PMC3836734.
32. Bell CH, Pantophlet R, Schiefner A, Cavacini LA, Stanfield RL, Burton DR, et al. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. Journal of molecular biology. 2008; 375(4):969-78. doi: 10.1016/j.jmb.2007.11.013 PMID: 18068724; PubMed Central PMCID: PMC2289799.
33. Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, et al. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. PLOS one. 2013; 8(8):e72054. doi: 10.1371/journal.pone.0072054 PMID: 23991039; PubMed Central PMCID: PMC3753353.
34. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009; 326 (5950):285-9. doi: 10.1126/science.1178746 PMID: 19729618; PubMed Central PMCID: PMC3335270.
35. Dennison SM, Anasti K, Scearce RM, Sutherland L, Parks R, Xia SM, et al. Nonneutralizing HIV-1 gp41 envelope cluster II human monoclonal antibodies show polyreactivity for binding to phospholipids and protein autoantigens. J Virol. 2011; 85(3):1340-7. doi: 10.1128/JVI.01680-10 PMID: 21106741; PubMed Central PMCID: PMC3020517.
36. Liao HX, Lynch R, Zhou T, Gao F, Alam SM, Boyd SD, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013; 496(7446):469- 76. doi: 10.1038/nature12053 PMID: 23552890; PubMed Central PMCID: PMC3637846.
37. Pejchal R, Doores KJ, Walker LM, Khayat R, Huang PS, Wang SK, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science. 2011; 334(6059):1097-103. doi: 10.1126/science.1213256 PMID: 21998254; PubMed Central PMCID: PMC3280215.
38. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, Julien JP, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011; 477(7365):466-70. doi: 10.1038/nature10373 PMID: 21849977; PubMed Central PMCID: PMC3393110.
39. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science. 2010; 329(5993):856-61. doi: 10.1126/science.1187659 PMID: 20616233; PubMed Central PMCID: PMC2965066.
40. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009; 458 (7238):636-40. doi: 10.1038/nature07930 PMID: 19287373.
41. Pietzsch J, Scheid JF, Mouquet H, Seaman MS, Broder CC, Nussenzweig MC. Anti-gp41 antibodies cloned from HIV-infected patients with broadly neutralizing serologic activity. J Virol. 2010; 84 (10):5032-42. doi: 10.1128/JVI.00154-10 PMID: 20219932; PubMed Central PMCID: PMC2863839.
42. Smith K, Garman L, Wrammert J, Zheng NY, Capra JD, Ahmed R, et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nature protocols. 2009; 4(3):372-84. doi: 10.1038/nprot.2009.3 PMID: 19247287; PubMed Central PMCID: PMC2750034.
43. Gach JS, Leaman DP, Zwick MB. Targeting HIV-1 gp41 in close proximity to the membrane using antibody and other molecules. Current topics in medicinal chemistry. 2011; 11(24):2997-3021. PMID: 22044228.
44. Croset A, Delafosse L, Gaudry JP, Arod C, Glez L, Losberger C, et al. Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells. Journal of biotechnology. 2012; 161(3):336-48. doi: 10.1016/j.jbiotec.2012.06.038 PMID: 22814405.
45. Pantophlet R, Aguilar-Sino RO, Wrin T, Cavacini LA, Burton DR. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology. 2007; 364(2):441-53. doi: 10.1016/j.virol.2007.03.007 PMID: 17418361; PubMed Central PMCID: PMC1985947.
46. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol. 2004; 78(23):13232-52. doi: 10.1128/JVI.78.23.13232-13252.2004 PMID: 15542675; PubMed Central PMCID: PMC524984.
47. McLellan JS, Pancera M, Carrico C, Gorman J, Julien JP, Khayat R, et al. Structure of HIV-1 gp120 V1/ V2 domain with broadly neutralizing antibody PG9. Nature. 2011; 480(7377):336-43. doi: 10.1038/nature10696 PMID: 22113616; PubMed Central PMCID: PMC3406929.
48. Julien JP, Lee JH, Cupo A, Murin CD, Derking R, Hoffenberg S, et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(11):4351-6. doi: 10.1073/pnas.1217537110 PMID: 23426631; PubMed Central PMCID: PMC3600498.
49. Posner MR, Cavacini LA, Emes CL, Power J, Byrn R. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120. Journal of acquired immune deficiency syndromes. 1993; 6(1):7-14. PMID: 8417177.
50. Wilkinson RA, Piscitelli C, Teintze M, Cavacini LA, Posner MR, Lawrence CM. Structure of the Fab fragment of F105, a broadly reactive anti-human immunodeficiency virus (HIV) antibody that recognizes the CD4 binding site of HIV type 1 gp120. J Virol. 2005; 79(20):13060-9. doi: 10.1128/JVI.79.20. 13060-13069.2005 PMID: 16189008; PubMed Central PMCID: PMC1235812.
51. Sanders RW, Derking R, Cupo A, Julien JP, Yasmeen A, de Val N, et al. A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLOS pathogens. 2013; 9(9):e1003618. doi: 10.1371/journal.ppat.1003618 PMID: 24068931; PubMed Central PMCID: PMC3777863.
52. Gach JS, Achenbach CJ, Chromikova V, Berzins B, Lambert N, Landucci G, et al. HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLOS one. 2014; 9(1):e85371. doi: 10.1371/journal.pone.0085371 PMID: 24454852; PubMed Central PMCID: PMC3893210.